Skip to main content
Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Biotechnology
Sector Health Technology
Employees 50
CEO Mr. Daniel R. Passeri
Address 21 Erie Street , Cambridge, MA 02139
Phone 1.617.949.2680
Website www.cuebiopharma.com

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and, Rodolfo Chaparro on December 31, 2014 and is headquartered in Cambridge, MA.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
Cue Biopharma, Inc. -1.21% -20.60%
Arcturus Therapeutics Holdings, Inc. -34.08% -55.57%
Seres Therapeutics, Inc. 63.72% -59.47%
AngioDynamics, Inc. -12.71% 85.13%
Treace Medical Concepts, Inc. -31.18% n/a

Statement Summary

as of 4:00 ET PM 12/02/2021
Total Assets (MRQ) 78.9 M
Total Liabilities (MRQ) 15.4 M
Shareholders’ Equity (MRQ) 63.5 M
Total Revenue (Annual) 2.4 M
Net Income (Annual) -13.0 M

Earnings And Estimates

as of 4:00 ET PM 12/02/2021

Current Qtr EPS Estimate -0.38
Current FY EPS Estimate -1.40
Long Term EPS Growth Estimate 3.00
Next Expected Earnings Date //

CUE vs S&P 500

as of 12/02/2021
Relative To
S&P 500
CUE
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:00 ET PM 12/02/2021
Fiscal Quarter Estimate Actual Surprise
06/2021 -0.42 -0.33 -20.86%
03/2021 -0.38 -0.41 +8.27%
12/2020 -0.35 -0.37 +5.75%
09/2020 -0.36 -0.34 -6.59%
06/2020 -0.41 -0.38 -6.17%
03/2020 -0.33 -0.48 +43.71%
12/2019 -0.45 -0.37 -17.32%
09/2019 -0.44 -0.31 -29.55%

Financial Strength

as of 4:00 ET PM 12/02/2021
Pre-Tax Margin -542.51
Net Margin 61.93
Operating Margin -543.55
Return On Equity -62.06
Return On Assets -50.55
Inventory Turnover (TTM) 0.00
Sales Growth (MRQ) n/a

Ratios

as of 4:00 PM ET 12/02/2021
Price/Earnings (TTM) n/a
Price/Book (MRQ) 6.07
Price/Cash Flow (TTM) 0.00
Book Value (MRQ) 2.03
Quick Ratio (MRQ) 4.58
Current Ratio (MRQ) 4.58
Total Debt/Equity (MRQ) 0.06

Short Interest

as of 4:00 PM ET 12/03/2021
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares 0 0
Short Interest Ratio 0.0 0.0
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:00 ET PM 12/02/2021
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Consensus Estimate $-0.38 $-0.33
# of Estimates 3 4
High Estimate $-0.31 $-0.10
Low Estimate $-0.41 $-0.45
Year Ago EPS $-0.37 $-0.41
Year Over Year Growth Estimate 2.97% -20.91%
Current Yr
(12/2021)
Next Yr
(12/2022)
Consensus Estimate $-1.40 $-1.71
# of Estimates 5 5
High Estimate $-0.97 $-1.48
Low Estimate $-1.60 $-2.07
Year Ago EPS $-1.56 $-1.40
Year Over Year Growth Estimate -10.38% 22.60%
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Current Year
(12/2021)
Next Year
(12/2022)
Consensus Estimate $-0.38 $-0.33 $-1.40 $-1.71
# of Estimates 3 4 5 5
High Estimate $-0.31 $-0.10 $-0.97 $-1.48
Low Estimate $-0.41 $-0.45 $-1.60 $-2.07
Year Ago EPS $-0.37 $-0.41 $-1.56 $-1.40
Year Over Year Growth Estimate 2.97% -20.91% -10.38% 22.60%

Insider Information Summary

as of 11/30/2021
% Insiders - 3.39%
% Remaining Total Shares - 96.61%
Current 1 Month
Net Insider Transaction 65.92 K 70.63 K
Shares Bought 181.16 K 139.65 K
Shares Sold 115.24 K 69.02 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

Recent Articles from TheStreet

Tech Rally Sends Hang Seng To Best Gain This Month As Traders Weigh Covid-19 Fallout In China

Market Dancing Like a 'Puppet on a String'

In the current state of the world, investors are ignoring two key truths, Jim Collins says.

Wall Street Lead

Cramer's Mad Money Recap 12/3: DocuSign, GameStop, Costco

Valuations for many stocks are high, says Jim Cramer. That means investors should be on the lookout for potential shocks and new buying opportunities.

lazy bear sh

The Bear is Hiding in Plain Sight

James 'Rev Shark" Deporre says the disconnect between mega cap stocks holding up the market indexes and struggling shares of many other companies is only getting worse.

Elaine Paul Lead

Lyft Taps Amazon, Disney Veteran Elaine Paul as CFO

Paul has worked at Amazon Studios and Disney in the past and led teams across finance, strategy, analytics and technology.

Facebook Lead

Facebook Tests Bill-Splitting Feature In Messenger

Known as Split Payments, the feature is set to launch for U.S. users next week.

Facebook Meta Logo Lead

Facebook in Bear Market, but Morningstar Says It's Undervalued

'We have continue to rate [Meta Platforms] a wide-moat firm with a solid network effect and intangible assets,' Morningstar said.

Cannabis Weed Marijuana Federal Lead

Cannabis Tax Revenue to Leap, Exceeding Take From Alcohol: Barclays

U.S. states collected about $2 billion in tax revenue last year, and that number could jump to $12 billion by 2030, according to a report.

Omicron COVID-19 Lead

WHO Says Don't Panic Over Omicron, Delta Still Dominant

The World Health Organization said it knows of no deaths resulting from omicron, with delta accounting for 99% of Covid infections.

Robin Williams' Suicide Seizes Google's Top Searches of 2014

Spotify Removes Tracks From John Mulaney, Robin Williams And Other Popular Comedians

The move seems to come as part of a rights dispute with a new comedy copyright organization

China's Tech Stock Comeback Faces Earnings Test From Alibaba, Meituan Amid Slower Growth And Tougher Regulations

What Is Going On With Alibaba Stock?

Ever since a disappointing earnings report, shares of the Chinese e-commerce giant Alibaba (BABA) have been on a downward spiral.